HAVE QUESTIONS?
Review our FAQs to learn more about ICOTYDE
The IL-23 pathway
IL-23 and its receptor (IL-23R) play a crucial role in regulating immune responses, including chronic inflammatory and autoimmune diseases like psoriasis.3
Designed to be highly stable in the Gl tract1,4
ICOTYDE is cleared via the kidneys and not metabolized in the liver.1,4
ICOTYDE
ICOTYDE targets IL-23 pathway and inhibits the IL-23/IL-23R–dependent release of proinflammatory cytokines.1,2,5
View transcript
Watch the video to see how the first and only IL-23R targeted oral peptide works1,2
GI, gastrointestinal; IL-12Rβ1, interleukin-12 receptor subunit beta-1; IL-23, interleukin-23; IL-23R, interleukin-23 receptor; MOA, mechanism of action; PsO, psoriasis.
References: 1. ICOTYDE [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Fourie AM, Cheng X, Chang L, et al. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024;14(1):17515. doi:10.1038/s41598-024-67371-5 3. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6):461-467. 4. Knight B, Dallas S, Mardirosian S, et al. ADME profiling of targeted oral peptide JNJ-77242113 (icotrokinra). Poster presented at: American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting; May 28-31, 2025; Washington, DC. 5. Xiao W, Jiang W, Chen Z, et al. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025;10(1):74. doi:10.1038/s41392-024-02107-5